Results 1 to 12 of 12
Thread: Follistatin prejudice?
-
06-04-2011, 12:42 PM #1
Follistatin prejudice?
How do these type of peptides decifer between skeletal muscle and other muscle, like cardio or digestive?
-
06-04-2011, 12:55 PM #2
I was wondering the same thing Bencher... I have heard it only effects skeletal muscle, i dont really want a 12 lb heart... I would like to know the same thing, REPS
"But God demonstrates His own love for us in this: while we were yet sinners Christ died for us."
– Romans 5:8
https://www.facebook.com/48PhysiqueEnhancement
-
06-04-2011, 01:12 PM #3
this is why i am sitting back and watching
but here is some info:
for one my reccomendation is Ace-031 over Folli to start with, and for the record, Gen X will have this in very soon...a "true" Ace-031 available for purchase...
Ace-031:
this comes from a study ill cite at the bottom:
"This is the first report that inhibition of negative regulators of skeletal muscle by a soluble form of activin type IIB receptor (ACE-031) increases muscle mass independent of fiber-type expression. This finding is distinct from the effects of selective pharmacological inhibition of myostatin (GDF-8), which predominantly targets type II fibers"
Type II muscle fibers are ALL Anaerobic muscle tissue fibers.
as far as the effects on cardio and digestive muscle systems, not research is available focusing on that so thats still to b seen
hope this gives some
link to study:
http://www.ncbi.nlm.nih.gov/pubmed/20466801
-
06-04-2011, 01:46 PM #4
Swole, thanks. GenX told me it would be a couple weeks till they get both in. I will look at the ACE.
-
06-04-2011, 01:53 PM #5
Wonder if IM to the muscle being worked would cut down on residual issues.
-
06-04-2011, 01:54 PM #6
Lots of supporting info on ACE 031
I am very excited to give this product a shot. WIl be honest, the only reason I have not tried follistatin is because Extreme Peps does not have it yet. But they do have ACE 031.
Read this
Acceleron Presents Preliminary ACE-031 Results from a Phase 1 Multiple Ascending Dose Study in Healthy Volunteers
Cambridge, Mass. – October 13, 2010 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced preliminary results from a Phase 1b study to assess the safety, tolerability and pharmacodynamic (PD) activity of ACE-031 following multiple ascending doses in healthy postmenopausal volunteers. ACE-031 is an investigational Protein therapeutic designed to build muscle and increase strength by blocking proteins that inhibit muscle growth. In the trial, ACE-031 was generally welltolerated with rapid and sustained effects on muscle, bone and fat. Preliminary results from this randomized, placebo-controlled study were presented at the 15th International Congress of the World Muscle Society in Kumamoto, Japan.
The ACE-031 Phase 1b study (A031-02) randomized 60 healthy postmenopausal women in 6 cohorts of 10 subjects each to receive ACE-031 or placebo (8:2) at dose levels ranging from 0.1 to 3 mg/kg given by subcutaneous injection every two or four weeks for a total of three or two doses, respectively, over a four week period. Subjects were followed for 12 weeks after their last dose. Lean mass (measured by DXA scans) and muscle volume of the thigh (assessed by MRI scans) were obtained at baseline and weeks 5, 8 and 16. Other PD endpoints included biomarkers of bone formation, bone resorption and fat metabolism, and measures of muscle strength and function. Although this safety study was not powered to assess statistically significant changes in these PD endpoints, multiple exploratory statistical analyses were performed on the data presented at the meeting. For a more detailed description of the study design, visit clinicaltrials.gov and query study identifier NCT00952887.
“The preliminary results of this multiple dose study in healthy volunteers confirm and expand upon the encouraging results observed previously in the single dose study of ACE-031,” said Matthew Sherman, MD, Chief Medical Officer of Acceleron. “These data are encouraging as we continue the development of ACE-031 in the ongoing Phase 2 study in patients with Duchenne Muscular Dystrophy.”
Summary of Preliminary ACE-031 Phase 1b Study Results:
- Safety, Tolerability and Pharmacokinetics: ACE-031 was generally well tolerated at all dose levels. The most common adverse events (AEs) included injection site reactions, headaches and nosebleeds. The majority of AEs were mild and transient. ACE-031 had a half-life of approximately 12 days, supportive of dosing every 2-4 weeks.
- Lean Mass: Mean total body lean mass measured by DXA at day 36 increased by 5.2% from baseline in the group receiving ACE-031 at 1 mg/kg every 2 weeks. This was statistically significant compared to the 0.4% increase in the placebo group (p=0.008) and was sustained through day 57. Significant increases were also seen at doses of 2 and 3 mg/kg every 4 weeks.
- Muscle Volume: Mean thigh muscle volume measured by MRI at day 36 increased by 4.1% from baseline in the group receiving ACE-031 at 1 mg/kg every 2 weeks compared to 1.1% in the placebo group (p=0.012). Significant increases were also seen at 2 mg/kg given every 4 weeks. No statistically significant changes were observed in grip strength or functional tests in this healthy volunteer safety study.
- Bone Density: ACE-031 therapy led to a rapid and significant increase in a biomarker of bone formation (BSAP) and decrease in a biomarker of bone resorption (CTX) versus placebo. Consistent with these effects, lumbar spine bone mineral density by DXA increased up to 3.4% in the 2 mg/kg every 4 week group from baseline to day 113, compared with a decrease of 1.5% in the placebo group (p=0.001).
- Fat: ACE-031 treatment led to significantly altered biomarkers of fat metabolism (increased adiponectin and decreased leptin) by day 8. Total body fat mass measured by DXA decreased up to 8.2% from baseline at day 113 in the 3 mg/kg every 4 week group compared with an increase of 0.5% in the placebo group (p=0.024).
About ACE-031
ACE-031 is an investigational Protein therapeutic designed to build muscle and increase strength by inhibiting signaling through a cell surface receptor called activin receptor type IIB (ActRIIB). ACE-031 is a recombinant fusion Protein that is produced by joining a portion of the human ActRIIB receptor to a portion of a human antibody. This creates a freely circulating, decoy version of ActRIIB which interferes with proteins, such as GDF-8 (myostatin), that normally limit the growth and regeneration of muscle by binding to and activating endogenous ActRIIB. Recent preclinical and clinical studies with ACE-031 suggest that blocking signaling through ActRIIB may be a way to increase muscle mass and improve muscle strength and function. In a range of animal models of muscle disease, including models of muscular dystrophy, muscle loss related to corticosteroid treatment, androgen deprivation or advanced age, ACE-031 increased muscle mass, strength and physical function. Unlike the mutation specific RNA-based therapeutics in clinical development for Duchenne Muscular Dystrophy (DMD), ACE-031 could potentially benefit patients with DMD, irrespective of the underlying genetic mutation. ACE-031 is being developed in collaboration with Shire.
BUY ACE-031 AT EXTREME PEPTIDE
-
06-04-2011, 01:59 PM #7
-
06-04-2011, 02:00 PM #8
- Join Date
- May 2011
- Location
- yteicos cilobana
- Posts
- 98
- Rep Power
- 0
-
06-04-2011, 02:13 PM #9
Protein protein recognition. Proteins involved in biological pathways have evolved to recognize their cohort partners. However, at non-physiologic concentrations and conditions abberent interactions can occur. Also, when such proteins are manipulated such as with modifying groups or alteration of Amino acid sequence, for instance for pharmaceutical use, their specificity can be altered. \\an example of this can be seen in melanotan II in comparison to the native form alpha melanocortin. The former has been cyclized through lactonization making ti approximately 100 times more potent. Not only does it interact with MT1 receptor in the dermis but also with MT II and MTIII in the gut and brain leading to nausea and spontaneous erections.
Bottom line is protein interactions are a delicate balance designed by nature to work within specific conditions.Last edited by toxic Avenger; 06-04-2011 at 02:14 PM.
-
06-04-2011, 04:18 PM #10
Thank ya Toxic. So basically these amino acid complexs are designed to match particular tissues?
-
06-07-2011, 02:02 PM #11
Any other input from anyone?
-
06-09-2011, 12:25 PM #12
- Join Date
- Feb 2009
- Location
- United States
- Posts
- 72
- Rep Power
- 456
Bookmarks